Physician profile
Michael Herlevic
NPI 1851362628
$10,254.98
in general payments reported to CMS, 2019-2025
40 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $1,270 · 2021: $1,204 · 2022: $1,362 · 2023: $1,566 · 2024: $1,348 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,062.83 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,038.42 | 2019-2025 | |
| Astellas Pharma US INC | $1,021.52 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $899.64 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $731.84 | 2021-2025 | Rexulti |
| Amgen INC. | $546.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $460.20 | 2019-2024 | Breztri |
| Glaxosmithkline, LLC. | $422.59 | 2019-2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $374.17 | 2020-2022 | |
| Lilly USA, LLC | $363.78 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $319.40 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $292.78 | 2020-2024 | Belsomra, Verquvo, Gardasil |
| Boston Scientific Corporation | $249.16 | 2023-2025 | Advantage System, Bulkamid - Bulkamid Urethral Bulking Pack 2ml (Ous) |
| Allergan, INC. | $177.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.23 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herlevic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.